Path to Personalized Medicine for Type 2 Diabetes Mellitus: Reality and Hope
,
Abstract
Type 2 diabetes mellitus (T2DM) is recognized as a public health problem and increasingly prevalent illness. Key elements of the guideline for diabetes care are based on evidence-based medicine approach and apply for population, not individuals. However, individualized care can improve diabetes management. Personalized medicine is otherwise called precision medicine tries to find better prediction, prevention, and intervention for T2DM individuals. Precision medicine in diabetes refers to the utility of genomics data of a patient with diabetes to provide the most effective diagnosis strategies and treatment plans. Over 100 genetic loci influence susceptibility to T2DM. Genomics data together with the potential of other “Omics” and clinical evidence-based data will lead to diabetes care improvement in the context of personalized medicine in the near future. Breakthrough of technologies enables much greater improvements in the understanding of individual variations that may alter the T2DM outcome. This article represents a comprehensive review of current knowledge on the impact of personalized medicine in T2DM.
Standards of Medical Care in Diabetes-2017: Summary of Revisions. Diabetes Care 2017;40:S4-S5.
Rahelic D. 7th Edition of Idf Diabetes Atlas--Call for Immediate Action. Lijec Vjesn 2016;138:57-8.
Almgren P, Lehtovirta M, Isomaa B, Sarelin L, Taskinen MR, Lyssenko V, et al. Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study. Diabetologia 2011;54:2811-9.
Zhou K, Pedersen HK, Dawed AY, Pearson ER.Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. Nat Rev Endocrinol2016;12:337-46.
Decode Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
Glauber HS, Rishe N, Karnieli E. Introduction to personalized medicine in diabetes mellitus. Rambam Maimonides Med J 2014;5:e0002.
Standards of Medical Care in Diabetes-2016: Summary of Revisions. Diabetes Care 2016;39:S4-5.
Glauber H, Karnieli E. Preventing type 2 diabetes mellitus: a call for personalized intervention. Perm J
;17:74-9.
Grant RW, Wexler DJ. Personalized medicine in Type 2 diabetes: what does the future hold? Diabetes Manag
;2:199-204.
DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013;36:S127-38.
Kaul N, Ali S. Genes, Genetics, and Environment in Type 2 Diabetes: Implication in Personalized Medicine. DNA Cell Biol 2016;35:1-12.
Pearson ER. Personalized medicine in diabetes: the role of 'omics' and biomarkers. Diabet Med 2016;33:712-7.
Holt RI. Personalized medicine for diabetes: a special issue. Diabet Med 2016;33:711.
Gillman MW, Hammond RA. Precision Treatment and Precision Prevention: Integrating "Below and Above the Skin". JAMA Pediatr 2016;170:9-10.
Ashley EA. Towards precision medicine. Nat Rev Genet 2016;17:507-22.
Fradkin JE, Hanlon MC, Rodgers GP. NIH Precision Medicine Initiative: Implications for Diabetes Research. Diabetes Care 2016;39:1080-4.
Harper CC. Personalized medicine in diabetes: regulatory considerations. J Diabetes Sci Technol 2009;3:739-42.
Rich SS, Cefalu WT. The Impact of Precision Medicine in Diabetes: A Multidimensional Perspective. Diabetes Care 2016;39:1854-7.
Spiegel AM, Hawkins M. 'Personalized medicine' to identify genetic risks for type 2 diabetes and focus prevention: can it fulfill its promise? Health Aff 2012;31:43-9.
Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes 2000;49:2201-7.
Jia W. Personalized medicine of type 2 diabetes. Front Med 2013;7:1-3.
Bailey CJ. The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future. Clin Pharmacol Ther 2015;98:170-84.
Mizzi C, Peters B, Mitropoulou C, Mitropoulos K, Katsila T, Agarwal MR, et al. Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics 2014;15:1223-34.
Zhou K, Donnelly L, Yang J, Li M, Deshmukh H, Van Zuydam N, et al. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol 2014;2:481-7.
Liao WL, Tsai FJ. Personalized medicine in Type 2 Diabetes. Biomedicine 2014;4:8.
Dawed AY, Zhou K, Pearson ER. Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. Pharmacogenomics Pers Med 2016;9:17-29.
Semiz S, Dujic T, Causevic A. Pharmacogenetics and personalized treatment of type 2 diabetes. Biochem Med 2013;23:154-71.
Singh S, Usman K, Banerjee M. Pharmacogenetic studies update in type 2 diabetes mellitus. World J Diabetes2016;7:302-15.
Avery P, Mousa SS, Mousa SA. Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine. Pharmacogenomics Pers Med 2009;2:79-91.
Della-Morte D, Palmirotta R, Rehni AK, Pastore D, Capuani B, Pacifici F, et al. Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors. Pharmacogenomics 2014;15:2063-82.
Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 2015;36:2288-96.
Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008;83:273-80.
Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 2009;58:1434-9.
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009;58:745-9.
Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, Bennett AJ, et al. Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet 2016;48:1055-9.
Hwang YC. Sulfonylurea: Personalized Medicine for Type 2 Diabetes. Endocrinol Metab 2015;30:467-8.
Kleinberger JW, Pollin TI. Personalized medicine in diabetes mellitus: current opportunities and future prospects. Ann N Y Acad Sci 2015;1346:45-56.
Loganadan NK, Huri HZ, Vethakkan SR, Hussein Z.Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation. Pharmacogenomics J 2016;16:209-19.
Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011;124:S3-18.
Chon S, Gautier JF. An Update on the Effect of Incretin- Based Therapies on beta-Cell Function and Mass. Diabetes Metab J 2016;40:99-114.
t Hart LM, Fritsche A, Nijpels G, van Leeuwen N, Donnelly LA, Dekker JM, et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes 2013;62:3275-81.
Tonjes A, Kovacs P. SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes? Pharmacogenomics 2013;14:825-33.
Lotta LA, Sharp SJ, Burgess S, Perry JR, Stewart ID, Willems SM, et al. Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis. JAMA 2016;316:1383-91.
Lyssenko V, Bianchi C, Del Prato S. Personalized Therapy by Phenotype and Genotype. Diabetes Care 2016;39:S127-36.
Florez JC. Precision Medicine in Diabetes: Is It Time? Diabetes Care 2016;39:1085-8.
Sun X, Sui W, Wang X, Hou X, Ou M, Dai Y, et al. Whole-genome re-sequencing for the identification of high contribution susceptibility gene variants in patients with type 2 diabetes. Mol Med Rep 2016;13:3735-46.
Prasad RB, Groop L. Genetics of type 2 diabetes-pitfalls and possibilities. Genes 2015;6:87-123.
McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010;363:2339-50.
Flannick J, Florez JC. Type 2 diabetes: genetic data sharing to advance complex disease research. Nat Rev Genet 2016;17:535-49.
Mohlke KL, Boehnke M. Recent advances in understanding the genetic architecture of type 2 diabetes. Hum Mol Genet 2015;24:R85-92.
Dorajoo R, Liu J, Boehm BO. Genetics of Type 2 Diabetes and Clinical Utility. Genes 2015;6:372-84.
Goodarzi MO. Genetics of Common Endocrine Disease: The Present and the Future. J Clin Endocrinol Metab 2016;101:787-94.
McCarthy MI. Genomic medicine at the heart of diabetes management. Diabetologia 2015;58:1725-9.
Persaud SJ, Jones PM. A Wake-up Call for Type 2 Diabetes? N Engl J Med 2016;375:1090-2.
Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, et al. The genetic architecture of type 2 diabetes. Nature 2016;536:41-7.
Shah HS, Gao H, Morieri ML, Skupien J, Marvel S, Pare G, et al. Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control
in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. Diabetes Care 2016;39:1915-24.
Raciti GA, Nigro C, Longo M, Parrillo L, Miele C, Formisano P, et al. Personalized medicine and type 2 diabetes: lesson from epigenetics. Epigenomics 2014;6:229-38.
Malandrino N, Smith RJ. Personalized medicine in diabetes. Clin Chem 2011;57:231-40.
Ahlqvist E, van Zuydam NR, Groop LC, McCarthy MI.The genetics of diabetic complications. Nat Rev Nephrol 2015;11:277-87.
| Files | ||
| Issue | Vol 55, No 3 (2017) | |
| Section | Review Article(s) | |
| Keywords | ||
| Type 2 diabetes mellitus Personalized medicine Omics Diabetes care | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
